All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was delighted to speak to Wendy Osborne, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
In this video, Wendy Osborne discusses the Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). She talks about the results from the phase I/II study that assesses the safety and efficacy of this bicistronic approach, which was designed to overcome CD19 escape and CAR T exhaustion.
Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL
ASCO 2016 | Extended Education Session – Immunotherapeutic Approaches to Treating Hematologic Malignancies
Presenters in this Extended Education Session on Immunotherapeutic Approaches included Max Topp, Philippe Armand, Carl June and Veronika...
Results from phase I ALEXANDER study investigating the first CAR T-cell therapy, AUTO3, plus pembrolizumab to target both CD19 and CD22 in the treatment of R/R DLBCL
Available CD19 chimeric antigen receptor (CAR) T-cells show activity in relapsed...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox